155 related articles for article (PubMed ID: 37317918)
1. Navigating Molecular Pathways: An Update on Drugs in Colorectal Cancer Treatment.
Maurya NS; Mani A
Curr Top Med Chem; 2023; 23(30):2821-2843. PubMed ID: 37317918
[TBL] [Abstract][Full Text] [Related]
2. Are Wnt/β-Catenin and PI3K/AKT/mTORC1 Distinct Pathways in Colorectal Cancer?
Prossomariti A; Piazzi G; Alquati C; Ricciardiello L
Cell Mol Gastroenterol Hepatol; 2020; 10(3):491-506. PubMed ID: 32334125
[TBL] [Abstract][Full Text] [Related]
3. Gankyrin sustains PI3K/GSK-3β/β-catenin signal activation and promotes colorectal cancer aggressiveness and progression.
He F; Chen H; Yang P; Wu Q; Zhang T; Wang C; Wei J; Chen Z; Hu H; Li W; Cao J
Oncotarget; 2016 Dec; 7(49):81156-81171. PubMed ID: 27835604
[TBL] [Abstract][Full Text] [Related]
4. Molecular dissection of effector mechanisms of RAS-mediated resistance to anti-EGFR antibody therapy.
Kasper S; Reis H; Ziegler S; Nothdurft S; Mueller A; Goetz M; Wiesweg M; Phasue J; Ting S; Wieczorek S; Even A; Worm K; Pogorzelski M; Breitenbuecher S; Meiler J; Paul A; Trarbach T; Schmid KW; Breitenbuecher F; Schuler M
Oncotarget; 2017 Jul; 8(28):45898-45917. PubMed ID: 28507280
[TBL] [Abstract][Full Text] [Related]
5. Phospholipase D1 Inhibition Linked to Upregulation of ICAT Blocks Colorectal Cancer Growth Hyperactivated by Wnt/β-Catenin and PI3K/Akt Signaling.
Kang DW; Lee BH; Suh YA; Choi YS; Jang SJ; Kim YM; Choi KY; Min DS
Clin Cancer Res; 2017 Dec; 23(23):7340-7350. PubMed ID: 28939743
[No Abstract] [Full Text] [Related]
6. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
7. Crosstalk between PI3K/Akt and Wnt/β-catenin pathways promote colorectal cancer progression regardless of mutational status.
Fleming-de-Moraes CD; Rocha MR; Tessmann JW; de Araujo WM; Morgado-Diaz JA
Cancer Biol Ther; 2022 Dec; 23(1):1-13. PubMed ID: 35944058
[TBL] [Abstract][Full Text] [Related]
8. Targeting the PI3K Signalling as a Therapeutic Strategy in Colorectal Cancer.
Fernandes MS; Sanches JM; Seruca R
Adv Exp Med Biol; 2018; 1110():35-53. PubMed ID: 30623365
[TBL] [Abstract][Full Text] [Related]
9. The PI3K/Akt/mTOR axis in colorectal cancer: Oncogenic alterations, non-coding RNAs, therapeutic opportunities, and the emerging role of nanoparticles.
Sanaei MJ; Baghery Saghchy Khorasani A; Pourbagheri-Sigaroodi A; Shahrokh S; Zali MR; Bashash D
J Cell Physiol; 2022 Mar; 237(3):1720-1752. PubMed ID: 34897682
[TBL] [Abstract][Full Text] [Related]
10. Activation of WNT/β-catenin signaling results in resistance to a dual PI3K/mTOR inhibitor in colorectal cancer cells harboring PIK3CA mutations.
Park YL; Kim HP; Cho YW; Min DW; Cheon SK; Lim YJ; Song SH; Kim SJ; Han SW; Park KJ; Kim TY
Int J Cancer; 2019 Jan; 144(2):389-401. PubMed ID: 29978469
[TBL] [Abstract][Full Text] [Related]
11. Potential targets for prevention of colorectal cancer: a focus on PI3K/Akt/mTOR and Wnt pathways.
Pandurangan AK
Asian Pac J Cancer Prev; 2013; 14(4):2201-5. PubMed ID: 23725112
[TBL] [Abstract][Full Text] [Related]
12. Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers.
Temraz S; Mukherji D; Shamseddine A
Int J Mol Sci; 2015 Sep; 16(9):22976-88. PubMed ID: 26404261
[TBL] [Abstract][Full Text] [Related]
13. Short interfering RNA in colorectal cancer: is it wise to shoot the messenger?
Chandramohan K; Balan DJ; Devi KP; Nabavi SF; Reshadat S; Khayatkashani M; Mahmoodifar S; Filosa R; Amirkhalili N; Pishvaei S; Sargazi-Aval O; Nabavi SM
Eur J Pharmacol; 2023 Jun; 949():175699. PubMed ID: 37011722
[TBL] [Abstract][Full Text] [Related]
14. Growth Factors, PI3K/AKT/mTOR and MAPK Signaling Pathways in Colorectal Cancer Pathogenesis: Where Are We Now?
Stefani C; Miricescu D; Stanescu-Spinu II; Nica RI; Greabu M; Totan AR; Jinga M
Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638601
[TBL] [Abstract][Full Text] [Related]
15. Resistance to dual blockade of the kinases PI3K and mTOR in KRAS-mutant colorectal cancer models results in combined sensitivity to inhibition of the receptor tyrosine kinase EGFR.
Belmont PJ; Jiang P; McKee TD; Xie T; Isaacson J; Baryla NE; Roper J; Sinnamon MJ; Lee NV; Kan JL; Guicherit O; Wouters BG; O'Brien CA; Shields D; Olson P; VanArsdale T; Weinrich SL; Rejto P; Christensen JG; Fantin VR; Hung KE; Martin ES
Sci Signal; 2014 Nov; 7(351):ra107. PubMed ID: 25389372
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of Bazhen decoction in the treatment of colorectal cancer based on network pharmacology, molecular docking, and experimental validation.
Lu S; Sun X; Zhou Z; Tang H; Xiao R; Lv Q; Wang B; Qu J; Yu J; Sun F; Deng Z; Tian Y; Li C; Yang Z; Yang P; Rao B
Front Immunol; 2023; 14():1235575. PubMed ID: 37799727
[TBL] [Abstract][Full Text] [Related]
17. Cellular signaling pathways implicated in metastasis of colorectal cancer and the associated targeted agents.
Liu X; Ji Q; Fan Z; Li Q
Future Oncol; 2015; 11(21):2911-22. PubMed ID: 26414153
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Potential of Targeting PI3K/AKT Pathway in Treatment of Colorectal Cancer: Rational and Progress.
Bahrami A; Khazaei M; Hasanzadeh M; ShahidSales S; Joudi Mashhad M; Farazestanian M; Sadeghnia HR; Rezayi M; Maftouh M; Hassanian SM; Avan A
J Cell Biochem; 2018 Mar; 119(3):2460-2469. PubMed ID: 28230287
[TBL] [Abstract][Full Text] [Related]
19. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines.
Vitiello PP; Cardone C; Martini G; Ciardiello D; Belli V; Matrone N; Barra G; Napolitano S; Della Corte C; Turano M; Furia M; Troiani T; Morgillo F; De Vita F; Ciardiello F; Martinelli E
J Exp Clin Cancer Res; 2019 Jan; 38(1):41. PubMed ID: 30691487
[TBL] [Abstract][Full Text] [Related]
20. Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance.
Ebrahimi N; Afshinpour M; Fakhr SS; Kalkhoran PG; Shadman-Manesh V; Adelian S; Beiranvand S; Rezaei-Tazangi F; Khorram R; Hamblin MR; Aref AR
Crit Rev Oncol Hematol; 2023 Feb; 182():103920. PubMed ID: 36702423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
